《大行》摩通把康方生物(09926.HK)从正面催化剂观察名单中移除 维持“增持”评级

阿斯达克财经
Yesterday

摩根大通表示,把康方生物(09926.HK) 从正面催化剂观察名单中移除。该催化剂即HARMONi-2试验的总生存期风险比数据发布。可能由于获利回吐,康方生物股价周一(28日)跌约12%,此前自3月底以来股价上涨超过15%。
该行对康方生物今年年中由其美国合作伙伴Summit发布的HARMONi数据公布前仍保持乐观,该公布将为AK112在全球三期试验中疗效表现的首次展示。

该行重申对康方生能“增持”评级,并视该股为中国生物科技股首选,目标价维持110元。(fc/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-30 12:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10